Swiss National Bank increased its stake in shares of Qiagen NV (NYSE:QGEN) by 5.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,085,912 shares of the company’s stock after buying an additional 60,586 shares during the quarter. Swiss National Bank owned about 0.48% of Qiagen worth $44,058,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Sycomore Asset Management bought a new position in shares of Qiagen in the 4th quarter valued at $86,182,000. American Century Companies Inc. lifted its stake in shares of Qiagen by 111.7% in the 4th quarter. American Century Companies Inc. now owns 995,508 shares of the company’s stock valued at $34,295,000 after acquiring an additional 525,268 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Qiagen by 4.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 12,615,185 shares of the company’s stock worth $434,593,000 after purchasing an additional 481,606 shares during the last quarter. Martingale Asset Management L P raised its position in Qiagen by 2,044.8% during the 1st quarter. Martingale Asset Management L P now owns 494,619 shares of the company’s stock worth $20,122,000 after purchasing an additional 471,558 shares during the last quarter. Finally, Millennium Management LLC raised its position in Qiagen by 172.7% during the 4th quarter. Millennium Management LLC now owns 650,831 shares of the company’s stock worth $22,421,000 after purchasing an additional 412,211 shares during the last quarter. 63.22% of the stock is currently owned by institutional investors and hedge funds.
Shares of QGEN traded up $0.36 during trading hours on Friday, hitting $40.55. The stock had a trading volume of 71,000 shares, compared to its average volume of 1,270,034. The firm has a market cap of $9.02 billion, a price-to-earnings ratio of 30.26, a P/E/G ratio of 2.46 and a beta of 0.84. The company has a quick ratio of 1.52, a current ratio of 1.69 and a debt-to-equity ratio of 0.54. Qiagen NV has a 1-year low of $32.33 and a 1-year high of $41.55. The business’s 50 day moving average is $38.71.
Several research analysts recently issued reports on the company. Zacks Investment Research lowered Qiagen from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. Goldman Sachs Group reaffirmed a “buy” rating on shares of Qiagen in a research report on Friday, June 21st. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a research report on Friday, April 12th. UBS Group assumed coverage on Qiagen in a research report on Friday, March 15th. They issued a “neutral” rating and a $42.00 price objective for the company. Finally, Wolfe Research assumed coverage on Qiagen in a research report on Thursday, May 30th. They issued a “peer perform” rating for the company. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Qiagen has an average rating of “Buy” and an average price target of $42.00.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Article: Holder of Record
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.